<DOC>
	<DOCNO>NCT00006373</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining chemotherapy peripheral stem cell bone marrow transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy follow autologous bone marrow transplantation peripheral stem cell transplantation treat patient non-Hodgkin 's lymphoma Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Followed Bone Marrow Peripheral Stem Cell Transplantation Treating Patients With Non-Hodgkin 's Lymphoma Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy intensive high dose chemotherapy consist topotecan , ifosfamide , etoposide follow autologous bone marrow peripheral blood stem cell transplantation term response rate , progression free survival , overall survival patient high risk non-Hodgkin 's lymphoma Hodgkin 's lymphoma . - Determine pharmacokinetic profile high dose topotecan etoposide patient . - Determine pharmacodynamics toxicity regimen patient . - Determine role either regulation DNA topoisomerase I II amount and/or activity term clinical response toxicity patient treated regimen . OUTLINE : Patients receive intensive high dose chemotherapy consist ifosfamide IV 2 hour follow topotecan IV 30 minute day -8 -6 etoposide IV continuously 24 hour day -5 -3 . Patients undergo autologous bone marrow peripheral blood stem cell transplantation day 0 . Patients follow 3 , 6 , 12 month , annually disease relapse , every 6 month death . PROJECTED ACCRUAL : A total 40 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm nonHodgkin 's lymphoma No lymphoblastic lymphoma Under 55 year age : Intermediate high grade aggressive disease relapse and/or fail least 2 salvage chemotherapy regimens OR Failed achieve complete response first line induction chemotherapy fail least 1 salvage chemotherapy regimen Low grade indolent disease relapse failed achieve complete response first line induction chemotherapy fail 2 salvage chemotherapy regimens 55 year age : Intermediate high grade aggressive disease relapse and/or failed achieve complete response first line induction chemotherapy Low grade indolent disease relapse failed achieve complete response first line induction chemotherapy OR Histologically confirm Hodgkin 's lymphoma Under 55 year age : Received least 2 prior salvage chemotherapy regimens 55 year age : Stage III IV disease relapse failed achieve remission combination induction chemotherapy Prior primary radiotherapy allow relapse high risk ( e.g. , recurrence radiation field , B symptom , liver bone marrow involvement ) No active leptomeningeal involvement severe symptomatic CNS disease Prior CSF tumor involvement allow asymptomatic evidence disease lumbar puncture tumor involvement MRI brain Solid tumor brain metastasis allow No evidence disease MRI physical exam follow optimal prior surgery and/or radiotherapy AND At least 3 month since prior radiotherapy NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : 18 64 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 2.0 mg/dL* SGOT SGPT great 2.5 time normal* No severe hepatic dysfunction NOTE : *Unless due primary malignancy Renal : Creatinine great 2.0 mg/dL OR Creatinine clearance least 60 mL/min Cardiovascular : No severe cardiac dysfunction Ejection fraction least 50 % MUGA scan Essential hypertension control medication allow Pulmonary : DLCO least 50 % normal OR No symptomatic obstructive restrictive disease Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception No active infection HIV negative No insulin dependent diabetes mellitus No uncompensated major thyroid adrenal dysfunction No significant skin breakdown tumor disease No prior malignancy within past 5 year except nonmelanoma skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Prior doxorubicin daunorubicin allow total dose great 450 mg/m2 No prior topotecan Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics Surgery : See Disease Characteristics Other : No concurrent nitroglycerin preparation angina pectoris No concurrent antiarrhythmic drug major ventricular arrhythmia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>